Top Institutional Investors

ADAR1 Capital Management, LLC — 13F Holdings & Portfolio

CIK 1940272 · latest 13F-HR filed 2026-08-14

Backtest portfolio

ADAR1 Capital Management, LLC manages $2.19B in 13F-reported U.S. long-equity assets across 277 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (11.01%), PTGX (5.39%), ROIV (5.11%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 44 new positions, exited 71, added to 131, and trimmed 61.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
3503 WILD CHERRY DRIVE
BUILDING 9
AUSTIN, TX 78738
Phone
(512) 254-3790
Filing Manager
ADAR1 Capital Management, LLC
AUSTIN, TX
Signatory
Stephen Scipione
Chief Compliance Officer
Loading holdings…
AUM

$2.19B

Long-equity book

Holdings

277

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+44 / −71 / ↑131 / ↓61

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • ABIVAX SA$85.3M +54.9%
  • STATE STR SPDR S&P 500 ETF T$47.0M +95.2%
  • AGIOS PHARMACEUTICALS INC$43.0M +904.4%
  • ZAI LAB LTD$37.2M +138.8%
  • PRAXIS PRECISION MEDICINES I$24.4M +5043.8%
Show all 131 →

Top Trims

  • SANOFI SA-$12.8M -84.0%
  • DBV TECHNOLOGIES S A-$12.5M -59.1%
  • DENALI THERAPEUTICS INC-$9.5M -26.3%
  • ARBUTUS BIOPHARMA CORP-$8.0M -56.8%
  • MOONLAKE IMMUNOTHERAPEUTICS-$8.0M -93.8%
Show all 61 →

New Positions

  • EDITAS MEDICINE INC$28.8M
  • VOR BIOPHARMA INC$12.5M
  • FAETH THERAPEUTICS INC$9.0M
  • ASCENDIS PHARMA A/S$7.6M
  • AMANAT ACQUISITION CORP$7.6M
Show all 44 →

Exited Positions

  • TERNS PHARMACEUTICALS INC$48.2M
  • BEAM THERAPEUTICS INC$34.5M
  • SCHOLAR ROCK HLDG CORP$20.0M
  • VERTEX PHARMACEUTICALS INC$6.7M
  • VIRIDIAN THERAPEUTICS INC$6.0M
Show all 71 →
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 ABIVAX SA ABVX 00370M103 $240.5M 11.01% 1,804,703 SH
2 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $117.8M 5.39% 960,863 SH
3 ROIVANT SCIENCES LTD ROIV G76279101 $111.7M 5.11% 3,157,008 SH
4 STATE STR SPDR S&P 500 ETF T SPY 78462F103 $96.4M 4.41% 129,087 SH
5 IMMUNOVANT INC IMVT 45258J102 $89.8M 4.11% 2,330,716 SH
6 ZAI LAB LTD ZLAB 98887Q104 $64.0M 2.93% 3,369,034 SH
7 AGIOS PHARMACEUTICALS INC AGIO 00847X104 $47.8M 2.19% 1,288,053 SH
8 CRINETICS PHARMACEUTICALS IN CRNX 22663K107 $45.7M 2.09% 1,222,080 SH
9 EA SERIES TRUST BOXX 02072L565 $39.5M 1.81% 337,125 SH
10 CYTOKINETICS INC CYTK 23282W605 $39.0M 1.79% 457,907 SH
11 SEPTERNA INC SEPN 81734D104 $31.5M 1.44% 940,747 SH
12 ANTERIS TECHNOLOGIES GLOBAL AVR 03675P102 $31.0M 1.42% 3,145,096 SH
13 EDITAS MEDICINE INC EDIT 28106W103 $28.8M 1.32% 8,889,000 SH
14 DENALI THERAPEUTICS INC DNLI 24823R105 $26.5M 1.21% 1,029,080 SH
15 SPYRE THERAPEUTICS INC SYRE 00773J202 $25.2M 1.15% 283,982 SH
16 VIR BIOTECHNOLOGY INC VIR 92764N102 $25.0M 1.15% 2,456,677 SH
17 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $24.9M 1.14% 74,253 SH
18 INSMED INC INSM 457669307 $24.4M 1.12% 228,520 SH
19 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $23.1M 1.05% 619,542 SH
20 VIKING THERAPEUTICS INC VKTX 92686J106 $22.4M 1.02% 574,038 SH
21 TAYSHA GENE THERAPIES INC TSHA 877619106 $20.7M 0.95% 3,040,466 SH
22 MONOPAR THERAPEUTICS INC MNPR 61023L207 $20.1M 0.92% 217,595 SH
23 OVID THERAPEUTICS INC OVID 690469101 $20.0M 0.91% 7,417,479 SH
24 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $19.7M 0.90% 387,718 SH
25 ENANTA PHARMACEUTICALS INC ENTA 29251M106 $19.6M 0.90% 1,344,510 SH
26 ISHARES TR Put IWM 464287655 $18.8M 0.86% 62,500 SH
27 STATE STR SPDR S&P 500 ETF T Put SPY 78462F103 $18.7M 0.85% 25,000 SH
28 NEKTAR THERAPEUTICS NKTR 640268306 $17.0M 0.78% 244,184 SH
29 INSPIRE MED SYS INC INSP 457730109 $16.7M 0.76% 374,617 SH
30 REVOLUTION MEDICINES INC RVMD 76155X100 $16.4M 0.75% 87,509 SH
31 ESTABLISHMENT LABS HLDGS INC ESTA G31249108 $15.9M 0.73% 185,619 SH
32 PROTHENA CORP PLC PRTA G72800108 $15.2M 0.70% 1,554,535 SH
33 RHYTHM PHARMACEUTICALS INC RYTM 76243J105 $15.1M 0.69% 136,158 SH
34 INHIBIKASE THERAPEUTICS INC IKT 45719W205 $15.0M 0.69% 7,387,205 SH
35 UNIQURE NV QURE N90064101 $15.0M 0.68% 324,672 SH
36 RALLYBIO CORP RLYB 75120L209 $14.8M 0.68% 926,352 SH
37 REGENERON PHARMACEUTICALS REGN 75886F107 $13.8M 0.63% 22,208 SH
38 INVENTIVA SA IVA 46124U107 $13.6M 0.62% 3,606,656 SH
39 SUTRO BIOPHARMA INC STRO 869367201 $13.4M 0.61% 404,014 SH
40 IONIS PHARMACEUTICALS INC IONS 462222100 $13.2M 0.60% 166,286 SH
41 BRIDGEBIO PHARMA INC BBIO 10806X102 $13.2M 0.60% 176,689 SH
42 SAREPTA THERAPEUTICS INC SRPT 803607100 $13.1M 0.60% 730,649 SH
43 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $12.6M 0.58% 3,365,118 SH
44 VOR BIOPHARMA INC VOR 929033207 $12.5M 0.57% 680,626 SH
45 SPDR SERIES TRUST BIL 78468R663 $12.4M 0.57% 135,585 SH
46 EQUILLIUM INC EQ 29446K106 $12.0M 0.55% 3,758,569 SH
47 ADLAI NORTYE LTD ANL 00704R109 $11.7M 0.54% 1,017,805 SH
48 CLIMB BIO INC CLYM 28658R106 $10.7M 0.49% 822,649 SH
49 SPDR SERIES TRUST Put XBI 78464A870 $10.7M 0.49% 67,400 SH
50 HELIX ACQUISITION CORP III HLXC G4444S107 $10.6M 0.49% 1,000,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $2.19B 277 0001940272-26-000015
2026-03-31 2026-05-18 $1.70B 311 0001940272-26-000005
2025-12-31 2026-02-18 $1.36B 270 0001940272-26-000003
2025-12-31 2026-02-17 $1.38B 270 0001940272-26-000002